Lactobacillus helveticus HY7804 Modulates the Gut–Liver Axis to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083557 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hyeonji Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Lactobacillus helveticus, Liver, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common type of liver disease worldwide. In a previous study, we confirmed that Lactobacillus helveticus HY7804 (HY7804) improves MASLD by suppressing the expression of mRNAs encoding genes related to hepatic lipogenesis, inflammation, and fibrosis in model mice. Here, we evaluated the ability of HY7804 to restore intestinal barrier function and modulate the gut microbiota, as well as improve MASLD symptoms. Mice fed an MASLD-inducing diet for 7 weeks received HY7804 (109 CFU/kg/day), the Type strain, or positive control (Pioglitazone) during the same period. HY7804 alleviated physiological (p < 0.001) and blood biochemical indicators and reduced MASLD activity scores (p < 0.05) on histological analysis. In addition, HY7804 increased the expression of genes related to fatty acid oxidation (p < 0.001); decreased the expression of apoptosis-related genes (p < 0.001); rescued the expression of tight junction (TJ)-related genes (p < 0.05); and suppressed the expression of pro-inflammatory cytokines and TLR4/MyD88/NF-κB signaling (p < 0.01) in the intestine. Finally, HY7804 modulated the composition of the gut microbiota in MASLD-induced mice. HY7804 increased the abundance of MASLD-suppressive Bacteroidaceae and Bacteroides, which positively correlated with the expression of TJ- and fatty acid oxidation-related genes. By contrast, HY7804 decreased the abundance of bacteria related to the progression of MASLD, including Cloastridaceae, Clostridium, Streptococcaceae, Lactococcus, and Lachnospiraceae, which correlated with intestinal immune responses and MASLD symptoms. In conclusion, L. helveticus HY7804 may be suitable as a functional supplement that alleviates MASLD symptoms and improves intestinal health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea.
ORCID-Profile: Hyeonji Kim, Kippeum Lee, Hyeonjun Gwon, Daehyeop Lee, Joo-Yun Kim
Zitieren
APA
Kim, H., Jeon, H. J., Jeong, J. W., Lee, K., Gwon, H., Lee, D., Kim, J. Y., Shim, J. J., & Lee, J. H. (2025). Lactobacillus helveticus HY7804 Modulates the Gut–Liver Axis to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083557
Vancouver
Kim H, Jeon HJ, Jeong JW, Lee K, Gwon H, Lee D, et al. Lactobacillus helveticus HY7804 Modulates the Gut–Liver Axis to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083557
BibTeX
@article{Kim2025,
author = {Kim, Hyeonji and Jeon, Hye-Jin and Jeong, Ji-Woong and Lee, Kippeum and Gwon, Hyeonjun and Lee, Daehyeop and Kim, Joo-Yun and Shim, Jae-Jung and Lee, Jae-Hwan},
title = {Lactobacillus helveticus HY7804 Modulates the Gut–Liver Axis to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083557}
}
EUVIMED